Cargando…

A prospective real‐world study of the diffuse‐type tenosynovial giant cell tumor patient journey: A 2‐year observational analysis

BACKGROUND AND OBJECTIVES: Diffuse‐tenosynovial giant cell tumor (D‐TGCT) is a rare, locally aggressive, typically benign neoplasm affecting mainly large joints, representing a wide clinical spectrum. We provide a picture of the treatment journey of D‐TGCT patients as a 2‐year observational follow‐u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernthal, Nicholas M., Healey, John H., Palmerini, Emanuela, Bauer, Sebastian, Schreuder, Hendrik, Leithner, Andreas, Martin‐Broto, Javier, Gouin, Francois, Lopez‐Bastida, Julio, Gelderblom, Hans, Staals, Eric L., Burke, Zachary D., Geiger, Erik J., Spierenburg, Geert, Laeis, Petra, Beyerlein, Elisabeth, Ye, Xin, van de Sande, Michiel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Cutaneous, Melanoma, Sarcoma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804718/ https://www.ncbi.nlm.nih.gov/pubmed/36006054 http://dx.doi.org/10.1002/jso.27067

Ejemplares similares

Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies
por: Palmerini, Emanuela, et al.
Publicado: (2023)

Risk factors for local atypical fibroxanthoma recurrence and progression to pleomorphic dermal sarcoma: A meta‐analysis of individualized participant data
por: Ørholt, Mathias, et al.
Publicado: (2022)

Synovial sarcomas: A single surgeon experience of 130 cases
por: Andreani, Lorenzo, et al.
Publicado: (2022)

Intralesional margin after excision of a high‐grade osteosarcoma: Is it a catastrophe?
por: Tsagkozis, Panagiotis, et al.
Publicado: (2022)

Subcostal lymph nodes: An unusual sentinel lymph node basin in cutaneous melanoma
por: Marsh, Katherine M., et al.
Publicado: (2022)

The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study
por: Bernthal, Nicholas M., et al.
Publicado: (2021)

Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors
por: Lewis, James H., et al.
Publicado: (2020)

External validation and adaptation of a dynamic prediction model for patients with high‐grade extremity soft tissue sarcoma
por: Rueten‐Budde, Anja J., et al.
Publicado: (2020)

Obesity is not associated with disease‐free interval, melanoma‐specific survival, or overall survival in patients with clinical stage IB‐II melanoma after SLNB
por: Deckers, Eric A., et al.
Publicado: (2021)

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T‐VEC)
por: Mulder, Evalyn E. A. P., et al.
Publicado: (2021)

Clinicopathologic models predicting non‐sentinel lymph node metastasis in cutaneous melanoma patients: Are they useful for patients with a single positive sentinel node?
por: Rentroia‐Pacheco, Barbara, et al.
Publicado: (2021)

Outcome after treatment for sebaceous carcinoma: A multicenter study
por: In 't Veld, Eva Huis, et al.
Publicado: (2022)

Factors associated with disease‐free and abdominal recurrence‐free survival in abdominopelvic and retroperitoneal sarcomas
por: Bredbeck, Brooke C., et al.
Publicado: (2022)

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
por: Lacouture, Mario E., et al.
Publicado: (2016)

Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Spillane, Susan, et al.
Publicado: (2020)

Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma
por: Luke, Jason J.
Publicado: (2019)

Real‐World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR‐Merkel
por: Bhanegaonkar, Abhijeet, et al.
Publicado: (2021)

Multidisciplinary Care of BRAF‐Mutant Stage III Melanoma: A Physicians Perspective Review
por: Cornelius, Lynn A., et al.
Publicado: (2021)

Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma
por: Di Guardo, Lorenza, et al.
Publicado: (2021)

Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial
por: Kahana, Alon, et al.
Publicado: (2021)

Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy
por: Anstadt, Emily J, et al.
Publicado: (2022)

Management of Acral and Mucosal Melanoma: Medical Oncology Perspective
por: Jung, Seungyeon, et al.
Publicado: (2022)

Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020
por: Qian, Mollie F, et al.
Publicado: (2022)

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy
por: Atkinson, Thomas M, et al.
Publicado: (2023)

Prognostic Risk Stratification and End-of-Life Care Outcomes in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors
por: Grad, Robert N, et al.
Publicado: (2023)

Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Stukalin, Igor, et al.
Publicado: (2023)

Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission
por: Sadrolashrafi, Kaviyon, et al.
Publicado: (2023)

Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis
por: Yarza, Ramon, et al.
Publicado: (2023)

Single‐Center Experience with Ifosfamide Monotherapy as Second‐Line Treatment of Recurrent/Metastatic Osteosarcoma
por: Verschoor, Arie Jan, et al.
Publicado: (2019)

Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease
por: Healey, John H., et al.
Publicado: (2020)

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors
por: Gelderblom, Hans, et al.
Publicado: (2020)

Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID‐19 Pandemic
por: Martin‐Broto, Javier, et al.
Publicado: (2020)

Management of Soft Tissue Sarcomas in Extremities: Variation in Treatment Recommendations and Surveillance According to Specialty and Continent
por: Acem, Ibtissam, et al.
Publicado: (2021)

Efficacy and Safety of Adjuvant Radiotherapy in Re-excised Soft-tissue Sarcoma After Unplanned Resection
por: Allignet, Benoît, et al.
Publicado: (2023)

Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry
por: Lopez-Bastida, J., et al.
Publicado: (2021)

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
por: Zalcberg, John R., et al.
Publicado: (2021)

MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment
por: Spierenburg, Geert, et al.
Publicado: (2023)

Early symptoms of bone and soft tissue sarcomas: could they be diagnosed earlier?
por: George, A, et al.
Publicado: (2012)

Feasibility and Efficacy of Microwave Ablation Combined with Iodine‐125 Seed Implantation in Local Control of Recurrent Retroperitoneal Liposarcomas: Initial Clinical Experience
por: Lu, Mingjian, et al.
Publicado: (2017)

Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor
por: Menegaz, Brian A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_plqllbejcun8eq9evhiajgpkot